2/3
01:37 pm
gpcr
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
Low
Report
Obesity stocks slump on Novo's underwhelming 2026 sales forecast [Yahoo! Finance Canada]
1/31
03:15 pm
gpcr
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
Low
Report
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more [Seeking Alpha]
1/31
01:33 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at
Wall
1/24
05:10 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/23
06:57 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
1/22
11:58 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at JPMorgan Chase & Co. from $65.00 to $105.00. They now have an "overweight" rating on the stock.
1/20
08:42 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/19
08:01 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $102.00 price target on by analysts at The Goldman Sachs Group, Inc..
1/15
11:52 am
gpcr
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why [Yahoo! Finance]
Low
Report
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why [Yahoo! Finance]
1/11
04:16 pm
gpcr
Can This Stock Double Again in 2026? [Yahoo! Finance]
Low
Report
Can This Stock Double Again in 2026? [Yahoo! Finance]
1/8
09:53 am
gpcr
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 [Yahoo! Finance]
Neutral
Report
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 [Yahoo! Finance]
1/6
07:17 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
12/22
07:26 pm
gpcr
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
High
Report
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
12/19
09:09 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:40 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
12/17
08:30 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
12/13
01:10 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at
Wall St
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at
Wall St
12/12
10:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/12
08:06 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.
12/12
07:12 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/11
04:14 pm
gpcr
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs [Yahoo! Finance]
12/11
04:01 pm
gpcr
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
Low
Report
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
12/11
12:01 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc..
12/10
12:10 am
gpcr
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants [Yahoo! Finance]
12/9
11:15 pm
gpcr
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
Medium
Report
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants